Answers are grounded in this paper and cite their sources.
We assessed structured electronic health record evidence of etiologic recognition after persistent microcytosis became visible in genetically defined β-thalassemia carriers. In a genotype-first All of Us cohort, the landmark was the second complete blood count with mean corpuscular volume (MCV) <80 fL; recognition was defined by combined hemoglobinopathy test/result records and thalassemia diagnosis codes. Among carriers lacking evidence at the landmark, adjusted Cox models examined subsequent recognition by functional severity (β++ = 0, β+ = 1, β0 = 2), both before and after adding landmark MCV. Of 1,977 carriers, 852 had repeated complete blood counts, and 793 (93.1%) had persistent microcytosis. At the landmark, 560/793 (70.6%) lacked recognition evidence; 228/560 (40.7%) subsequently acquired it (5-year cumulative probability 32.6%, 95% confidence interval [CI] 28.6–36.9). Greater severity was associated with faster recognition (hazard ratio [HR] 1.37 per severity step, 95% CI 1.10–1.72). With MCV added, the severity HR was 1.15 (95% CI 0.89–1.47); the MCV HR was 0.78 per +5 fL (95% CI 0.66–0.92). Diagnosis-code-only endpoints yielded similar estimates. The documentation gap persisted under stringent observation requirements. Persistent, genotype-consistent microcytosis frequently preceded structured documentation of investigation or diagnosis. Associations with landmark MCV support a link between phenotypic visibility and recorded investigation or diagnosis, not proof of clinical awareness, missed diagnosis, or causal mediation.
No takes yet. Share an insight, caveat, or question.
Ali Hanbashi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: